Cargando…

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

BACKGROUND: A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of this Q4W regimen were based on population pharma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290887/ https://www.ncbi.nlm.nih.gov/pubmed/30215677 http://dx.doi.org/10.1093/annonc/mdy408

Ejemplares similares

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors
por: Zhao, X., et al.
Publicado: (2017)

Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors
por: Sheng, Jennifer, et al.
Publicado: (2021)

Which is the best schedule of autologous blood storage for pre-operative AIS patients? Every week or every 2 weeks
por: Tamai, Koji, et al.
Publicado: (2015)

Phase I study of gemcitabine using a once every 2 weeks schedule.
por: Vermorken, J. B., et al.
Publicado: (1997)

Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
por: Bei, Di, et al.
Publicado: (2020)

Inclusive production of isotopically resolved Li through Mg fragments by 480 MeV p + Ag reactions
por: Green, R E L, et al.
Publicado: (1983)

Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
por: Morita, Akimichi, et al.
Publicado: (2021)

Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
por: Taxonera, Carlos, et al.
Publicado: (2021)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
por: Stroes, Erik, et al.
Publicado: (2016)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas: What Is the Best Dosing and Schedule?
por: Mashhour, Karim, et al.
Publicado: (2020)

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
por: Peipert, John Devin, et al.
Publicado: (2020)

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
por: Müller-Wieland, Dirk, et al.
Publicado: (2019)

Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice
por: Calvo Moya, Marta, et al.
Publicado: (2023)

PS Coordination memorandum: Weekly schedule meeting
por: Von Dardel, G
Publicado: (1961)

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting
por: Kato, Renpei, et al.
Publicado: (2020)

As every year, 2016 ended with the Council Week
por: Staff Association
Publicado: (2017)

Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
por: Cheng, Karen, et al.
Publicado: (2019)

Effect of triptorelin 3.75 mg subcutaneously injection every 6 weeks on adult height in girls with idiopathic central precocious puberty
por: Liang, Yan, et al.
Publicado: (2015)

Addendum on the estimation of Module 0 PMT 480 nm quantum efficiency
por: Montarou, G
Publicado: (1997)

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
por: Vermeire, Séverine, et al.
Publicado: (2020)

‘I Know it was Every Week, but I Can't be Sure if it was Every Day: Domestic Violence and Women with Learning Disabilities
por: McCarthy, Michelle, et al.
Publicado: (2016)

Health benefits of late-onset metformin treatment every other week in mice
por: Alfaras, Irene, et al.
Publicado: (2017)

Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
por: Bajaj, G, et al.
Publicado: (2016)

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)

Test of charge symmetry in np elastic scattering at 480 MeV
por: Abegg, R, et al.
Publicado: (1986)

Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
por: Veatch, Joshua R, et al.
Publicado: (2020)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

FRI480 Uncovering The Mystery Of Macro TSH
por: Anwar, Farrah, et al.
Publicado: (2023)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

PS Coordination memorandum: Weekly schedule meeting weeks 28 August -2 September and 4 - 9 September
por: Von Dardel, G
Publicado: (1961)

Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
por: Lucas, T, et al.
Publicado: (2006)

PS Coordination memorandum: PS weekly schedule meeting, 19 January 1961
por: Von Dardel, G
Publicado: (1961)

Every Day Practice
por: Betty, E. G.
Publicado: (1886)

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis
por: Zhang, Chenli, et al.
Publicado: (2021)

Variability and cost implications of three generations of the Roche LightCycler® 480
por: Dullaert-de Boer, Maria, et al.
Publicado: (2018)

Graham Magnetics EPOCH 480 Magnetic Reel Tape
Publicado: (Late)

Structure in the $\pi ^{+} pi ^-$ system at 480 MeV
por: Dubal, L, et al.
Publicado: (1969)

480 Silvery-gray Hair Patient with neurologic deterioration
por: Gamez, Luisa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_g31uvrk2856krsrbp3pt3b6ks4